Efficacy of chloroquine, amodiaquine, sulphadoxine-pyrimethamine and combination therapy with artesunate in Mozambican children with non-complicated malaria
Autor: | Ricardo Thompson, Sonia Enosse, Llorenç Quintó, Mabunda S, Anita M. Rønn, P. L. Alonso, Fatima Abacassamo, Barreto A, Pascal Magnussen, Gómez-Olivé Fx, John J. Aponte |
---|---|
Rok vydání: | 2004 |
Předmět: |
Male
medicine.medical_specialty Sulfadoxine medicine.medical_treatment Population Plasmodium falciparum Amodiaquine Pharmacology chemistry.chemical_compound Antimalarials Chloroquine Internal medicine parasitic diseases medicine Animals Humans Malaria Falciparum education Mozambique education.field_of_study biology business.industry Public Health Environmental and Occupational Health Infant biology.organism_classification medicine.disease Drug Combinations Infectious Diseases Pyrimethamine Treatment Outcome chemistry Artesunate Child Preschool Parasitology Drug Therapy Combination Female business Malaria medicine.drug Follow-Up Studies |
Zdroj: | University of Copenhagen |
ISSN: | 1360-2276 |
Popis: | This paper reports a two-phase study in Manhiça district, Mozambique: first we assessed the clinical efficacy and parasitological response of Plasmodium falciparum to chloroquine (CQ), sulphadoxine-pyrimethamine (SP) and amodiaquine (AQ), then we tested the safety and efficacy in the treatment of uncomplicated malaria, of three combinations: AQ + SP, artesunate (AR) + SP and AQ + AR. Based on the WHO (1996, WHO/MAL/96.1077) in vivo protocol, we conducted two open, randomized, clinical trials. Children aged 6-59 months with axillary body temperatureor = 37.5 degrees C and non-complicated malaria were randomly allocated to treatment groups and followed up for 21 days (first and second trial) and 28 days (first trial). The therapeutic efficacy of AQ (91.6%) was better than that of SP (82.7%) and CQ (47.1%). After 14 days, 69% of the strains were parasitologically resistant to CQ, 21.4% to SP and 26% to AQ. Co-administration of AQ + SP, AR + SP and AQ + AR was safe and had 100% clinical efficacy at 14-day follow-up. The combination therapies affected rapid fever clearance time and reduced the incidence of gametocytaemia during follow-up. |
Databáze: | OpenAIRE |
Externí odkaz: |